Related Experiment Video

Updated: May 26, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR

X Li1, Y Lu, K Liang

  • 1Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Oncogene
|January 11, 2012
PubMed

Insights

Breast tumor kinase (Brk) sustains epidermal growth factor receptor (EGFR) signaling, explaining poor response to EGFR-targeted therapy in breast cancer. Brk inhibition sensitizes tumors to cetuximab, offering a new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Epidermal growth factor receptor (EGFR) signaling is crucial for mammary cell function.
  • Targeting EGFR offers limited therapeutic benefit in breast cancer, necessitating research into resistance mechanisms.

Purpose of the Study:

  • To elucidate a novel regulatory mechanism of EGFR signaling in breast cancer.
  • To investigate the role of breast tumor kinase (Brk)/protein-tyrosine kinase 6 (PTK6) in EGFR signaling and therapeutic response.

Main Methods:

  • Investigated the interaction between Brk and EGFR.
  • Assessed Brk's effect on EGFR degradation and ubiquitination.
  • Examined Brk's phosphorylation of EGFR at Y845.
  • Evaluated the impact of Brk modulation on breast cancer cell response to cetuximab.

Main Results:

  • Brk interacts with EGFR and sustains ligand-induced signaling.
  • Brk inhibits EGFR degradation by disrupting EGFR ubiquitination.
  • Brk directly phosphorylates EGFR at Y845, enhancing kinase activity.
  • Elevated Brk confers resistance to cetuximab; Brk knockdown sensitizes cells to cetuximab.

Conclusions:

  • Brk is a novel regulator of EGFR signaling and a key determinant of therapeutic response in breast cancer.
  • Brk's role in sustaining EGFR signaling presents a potential therapeutic target for overcoming resistance to EGFR-targeted therapies.

More Related Videos

Assaying Protein Kinase Activity with Radiolabeled ATP08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...